Global PV updates, mapped to your role.

1) Verify your internal signal assessment narrative for GLP-1 RAs reflects FDA’s statement that the preliminary evaluation does not suggest a causal link; 2) Check whether any company-facing statements, FAQs, or labeling change proposals referencing suicidality need to be updated for consistency with FDA’s current public position; 3) Log the FDA update in regulatory intelligence tracking and maintain monitoring for further FDA conclusions or requests (including the linked 13 Jan 2026 communication).

This update requires triage for Signal Validation, Vendor Oversight, Inspection Readiness; confirm local obligations and document follow-up actions.

Tga update requires triage for Label Governance, Signal Validation, Risk Management; confirm local obligations and document follow-up actions.

This update requires triage for Label Governance, Signal Validation, Risk Management; confirm local obligations and document follow-up actions.